Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 22 2021 - 4:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2021
Commission
File Number: 001-32371
SINOVAC
BIOTECH LTD.
No.
39 Shangdi Xi Road
Haidian
District
Beijing
100085, People’s Republic of China
(Address
of principal executive offices)
Indicate by check
mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F x Form 40-F ¨
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
CONTENTS
Explanatory Note
On February 21,
2021, Sinovac Biotech Ltd. (the “Company”) entered into a second amendment (the “Second Amendment”) to
the Amended and Restated Rights Agreement, dated as of February 22, 2019 (the “Amended and Restated Rights Agreement”),
as amended by the Amendment to Amended and Restated Rights Agreement dated as of February 19, 2020 (the “Amendment to
Amended and Restated Rights Agreement”), between the Company and Pacific Stock Transfer Company, as Rights Agent, to
extend the expiration date of the rights contained therein from February 22, 2021 to February 22, 2022.
The foregoing summary of the Second Amendment
is qualified in its entirety by reference to the full text of the Second Amendment, which is filed as Exhibit 4.1 hereto and is
incorporated herein by reference. A copy of the Amendment to Amended and Restated Rights Agreement and a summary of its material
terms were filed with the SEC on Form 6-K on February 21, 2020 (incorporated herein by reference by Exhibit 4.2). A copy of the
Amended and Restated Rights Agreement and a summary of its material terms were filed with the Securities and Exchange Commission
on Form 6-K on February 22, 2019 (incorporated herein by reference by Exhibit 4.3).
Incorporation
by Reference
The
summary of the Second Amendment above and Exhibit 4.1 attached hereto are hereby incorporated by reference into our registration
statements on Form S-8 filed with the Securities and Exchange Commission on September 10, 2009 (File No. 333-161827) and Form
S-8 filed with the Securities and Exchange Commission on September 4, 2013 (File No. 333-190980).
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
SINOVAC BIOTECH LTD.
|
|
|
|
|
By:
|
/s/ Nan Wang
|
|
Name:
|
Nan Wang
|
|
Title:
|
Chief Financial Officer
|
Date:
February 22, 2021
Exhibit Index
Exhibit 4.1
|
Second Amendment to Amended and Restated Rights Agreement dated as of February 21, 2021 between Sinovac
Biotech Ltd. and Pacific Stock Transfer Company, as Rights Agent
|
|
|
Exhibit 4.2
|
Amendment to Amended and Restated Rights Agreement, dated as of February 19, 2020, between Sinovac Biotech Ltd. and
Pacific Stock Transfer Company, as Rights Agent (incorporated by reference to Exhibit 4.1 of the Report on Form 6-K dated
February 21, 2020 of Sinovac Biotech Ltd.)
|
|
|
Exhibit 4.3
|
Amended and Restated Rights Agreement, dated as of February 22, 2019, between Sinovac Biotech Ltd. and Pacific Stock
Transfer Company, as Rights Agent, which includes the Form of Certificate of Designations of Series C Junior Participating
Preferred Shares as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred
Shares as Exhibit C (incorporated by reference to Exhibit 99.6 of the Report on Form 6-K dated February 22, 2019 of Sinovac
Biotech Ltd.)
|
|
|
Exhibit 99.1
|
Press Release
|
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Sep 2023 to Sep 2024